SCHEMBL13637817

SCHEMBL13637817

CC(=O)Oc1ccccc1-c1ccc2[nH]c(COc3ccc(C(F)(F)F)cc3)nc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.46
NPC1 O15118 7/20 0.46
RAB9A P51151 7/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
PKM P14618 1/20 0.46
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
MAOB P27338 1/20 0.44
TRPV1 Q8NER1 3/20 0.42
PDE10A Q9Y233 2/20 0.42
TP53 P04637 2/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4528906 0.87 TRPV1 (0.53) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL13637818 0.85 MAOB (0.45) BACE1NPC1RAB9ASMN1; SMN2LMNA
SCHEMBL4554435 0.85 ALDH1A1 (0.46) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL4521977 0.84 KDM4C (0.48) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL4515791 0.84 RAB9A (0.45) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL4536251 0.84 NPC1 (0.50) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL4528019 0.84 ALDH1A1 (0.46) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL4530613 0.84 ALDH1A1 (0.44) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL4528938 0.83 TRPV1 (0.45) NPC1RAB9ASMN1; SMN2LMNAHTT
SCHEMBL4515276 0.83 ALDH1A1 (0.45) NPC1RAB9ASMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612211-B2 Benzimidazole TRPV1 inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2009-11-03 US disclosed
WO-2008076752-A1 BENZIMIDAZOLE TRPV1 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-06-26 WO disclosed
US-20080146637-A1 BENZIMIDAZOLE TRPV1 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146637-A1 BENZIMIDAZOLE TRPV1 INHIBITORS TRPV1, TRPV2, TRPA1 BACE1 2425/4885NPC1 282/4885RAB9A 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.